Biolase Profit Margin

Biolase (BIOL) currently reports a profit margin of -34.84% as of September 2024. That compares with -50.17% in the prior-year period — up 30.6% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Biolase's profit margin history and peer comparisons.

Biolase's profit margin increased from -50.17% to -34.84% — a 30.6% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biolase's profit margin of -34.84% is lower than the Healthcare sector average of 15.58%. That is roughly 323.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Biolase's current -34.84% should be judged against Healthcare norms (sector average: 15.58%) and against BIOL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -34.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Biolase, and consider following BIOL for alerts when major investors trade the stock.